Venetoclax shows potential for R/R hairy cell leukemia

Published Date: 13 Mar 2023

Five out of six patients with relapsed or recurrent lymphoma responded to venetoclax alone or in combination with rituximab.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.

2.

Do I have prostate cancer? Why a simple PSA blood test alone won't give you the answer

3.

Radiation from CT scans could account for 5% of all cancer cases a year, study suggests

4.

According to a study, taking part in a clinical trial for cancer may not actually increase survival.

5.

Weight-Based and Fixed-Dose Pembrolizumab Compared in NSCLC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot